Subjects are monitored continuously by highly trained investigators and staff. Subject compliance and symptoms assessment are accurate and reproducible.
Our experienced team of principal investigators and clinicians are actively involved in the protocol design and conduct of all chamber studies.
Biogenics Research Chamber is ideal for proof of concept, dose ranging, mechanisms of action, and efficacy studies evaluating allergic rhinoconjunctivitis and asthma.
Our large database of potential study subjects and close cooperation with local academic investigators with expertise in molecular biology and genetics, allows us to perform studies at the leading edge of scientific discovery and design.
UPCOMING MEETINGS
June 22-26, 2013 Milan, Italy
European Academy of Allergy and Clinical Immunology and World Allergy Organization (EAACI-WAO) Conference
Please visit us at booth 305A
IN THE NEWS
Dr. Robert Jacobs will present an abstract entitled “Evaluation of ultra-rush immunotherapy for Virginia live oak in a pollen challenge chamber identifies cytokine and transcriptional correlates of protection” on Sunday, June 23, 2013 at the EEACI-WAO Conference in Milan, Italy.
